We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

A Study of Ketamine as an Antidepressant

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01441505
Recruitment Status : Unknown
Verified February 2013 by Colleen Loo, The University of New South Wales.
Recruitment status was:  Recruiting
First Posted : September 27, 2011
Last Update Posted : February 22, 2013
Information provided by (Responsible Party):

September 16, 2011
September 27, 2011
February 22, 2013
September 2011
December 2014   (Final data collection date for primary outcome measure)
Change from baseline on depression rating scales [ Time Frame: Before, 4 hours after, and 24 hours after ketamine session ]
Same as current
Complete list of historical versions of study NCT01441505 on ClinicalTrials.gov Archive Site
Psychiatric side effects (BPRS, CADSS) and memory tests [ Time Frame: Cognitive battery done before and after 3 weeks; side effects measured immediately before and 4 hours after each ketamine session in both phases. ]
Same as current
Not Provided
Not Provided
A Study of Ketamine as an Antidepressant
A Study of Ketamine as an Antidepressant

Recently, interest has emerged in the use of ketamine as an antidepressant. Recent placebo-controlled clinical trials administering a single dose and an open label trial giving repeated doses shown that ketamine is markedly superior to placebo at reducing depression, including in treatment-resistant patients, and that its antidepressant effects have a very rapid onset.

This clinical study consists of two phases. In Phase I, participants who satisfy inclusion criteria will receive ketamine at variable doses (0.1mg/kg-0.5mg/kg) or a placebo (saline, or 0.01mg/kg midazolam) once a week over up to 6 weeks. If participants qualify for Phase II, they will receive repeated sessions of ketamine at variable doses over three weeks. During both phases, mood, psychiatric, and neuropsychological outcomes will be measured.

This clinical study consists of two phases. In Phase I, participants will receive variable doses of intravenous, intramuscular, or subcutaneous ketamine (0.1-0.5mg/kg) or placebo (saline, or 0.01mg/kg midazolam) weekly for up to 6 consecutive weeks. Prior to receiving ketamine/placebo, participants' mood and psychiatric symptoms will be assessed. Once they have received their treatment, mood, psychiatric side effects, ketamine blood levels, heart rate, blood pressure and biomarkers will be assessed. Mood and cognitive performance be assessed again after 4 hours. Finally, mood will also be assessed the next day.

Some participants may be eligible to continue to Phase II. In this phase, participants will receive doses of ketamine approximately weekly for up to 6 months. During this phase, participants' mood, psychiatric, biomarkers and cognitive outcomes will be assessed.

The purpose of the trial is to investigate the antidepressant and safety effects of using ketamine as a treatment in depression.

Phase 2
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Major Depressive Episode
  • Drug: Ketamine
    Ketamine IV, IM, or SC will be administered in Phase I and II
  • Drug: Saline or Midazolam (active placebo)
    Saline, or midazolam 0.01mg/kg will be administered in Phase I
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
Unknown status
December 2014
December 2014   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Satisfy DSM-IV-TR criteria for Major Depressive Episode
  • 18 years or over
  • Able to give informed consent

Exclusion Criteria:

  • Diagnosis of schizophrenia, schizoaffective disorder, rapid cycling bipolar disorder, or current psychotic symptoms
  • Known sensitivity or contraindication to ketamine
  • Recent drug abuse
  • Pregnant
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
Contact information is only displayed when the study is recruiting subjects
HREC 10409
Not Provided
Not Provided
Colleen Loo, The University of New South Wales
The University of New South Wales
Wesley Hospital, Kogarah
Principal Investigator: Colleen K Loo, MB BS FRANZCP MD University of New South Wales
The University of New South Wales
February 2013

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP